𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The current place of high-dose immunoglobulins in the treatment of neuromuscular disorders

✍ Scribed by Frans G. A. van der Meché; Pieter A. van Doorn

Publisher
John Wiley and Sons
Year
1997
Tongue
English
Weight
114 KB
Volume
20
Category
Article
ISSN
0148-639X

No coin nor oath required. For personal study only.

✦ Synopsis

High-dose immunoglobulins for intravenous administration (IVIg) have originally been developed for substitution therapy in hypogammaglobulinemia. Over the last decade they are increasingly used in the treatment of immunemediated diseases. In this review the results in immune-mediated neuromuscular diseases are summarized. Positive effects are demonstrated in open studies in dermato-and polymyositis, myasthenia gravis, and inflammatory neuropathies. Properly conducted randomized clinical trials demonstrating the effect of IVIg are available in dermatomyositis, Guillain-Barre śyndrome, and chronic inflammatory demyelinating polyneuropathy, and smaller ones in multifocal motor neuropathy. In myasthenia gravis a trial is at present underway and only interim results are available. The results of a trial in the Lambert-Eaton myasthenic syndrome are in the process of publication. The therapeutic approach in individual patients is discussed, but often appears to be difficult. Considering chronic treatment with IVIg, proper long-term studies including cost-benefit studies are needed. Future developments aim for combination therapies, since IVIg and immune suppressants like prednisone are suggested to have a synergistic effect.

📜 SIMILAR VOLUMES

Intravenous immunoglobulin in the treatm
Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: Present status and practical therapeutic guidelines
✍ Marinos C. Dalakas 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 279 KB 👁 1 views

This review summarizes the current status of intravenous immunoglobulin (IVIg) in the treatment of autoimmune neuromuscular disorders and the possible mechanisms of action of the drug based on work in vivo, in vitro, and in animal models. Supply of idiotypic antibodies, suppression of antibody produ

Needle muscle biopsy in the investigatio
Needle muscle biopsy in the investigation of neuromuscular disorders
✍ Michel R. Magistris; André Kohler; Gianpaolo Pizzolato; Michael A. Morris; Anne 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 415 KB 👁 1 views

We have evaluated needle muscle biopsies in 220 patients with various neuromuscular disorders, using a method developed previously at Tuft's University. The method uses a 14-gauge needle propelled by an automatic device. An average of 3.5 samplings were taken per patient. Muscle samples were used fo

Activity of high-dose cyclophosphamide i
Activity of high-dose cyclophosphamide in the treatment of childhood malignant gliomas
✍ McCowage, Geoffrey B.; Friedman, Henry S.; Moghrabi, Albert; Kerby, Tracy; Ferre 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 225 KB 👁 2 views

Seventeen patients less than or equal to 20 years of age with newly diagnosed (n = 10) or recurrent (n = 7) malignant gliomas (anaplastic astrocytoma and glioblastoma multiforme) were treated with cyclophosphamide in association with hematopoietic cytokines (GM-CSF or G-CSF). Cyclophosphamide was gi

The Place of Milnacipran in the Treatmen
The Place of Milnacipran in the Treatment of Depression
✍ S. Kasper 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB 👁 2 views

Modern community-based studies have revealed high prevalence rates for major depression in adults. Despite this high prevalence, many depressed individuals do not seek treatment and only a minority of those that do are prescribed antidepressants. This paper considers the role of antidepressants, esp